Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

US11389480B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Joost Oppenheim · Bethesda, US
• Dimiter S. Dimitrov · Frederick, US
• De Yang · Frederick, US
• Xin Chen · Lexington, US
• Zhongyu Zhu · Frederick, US

Key dates

• Filing date: May 8, 2018
• Grant date: Jul 19, 2022
• Expiry date: May 28, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A human monoclonal antibody that specifically binds tumor necrosis factor receptor 2 (TNFR2), and a defucosylated form of the antibody, are described. The TNFR2-specific antibody was isolated from a human scFv phage display antibody library. The disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2+ CD4+ T regulatory cells in a dose- and time-dependent manner. Methods of using the TNFR2 antibodies, such as for tumor immunotherapy, are described.